Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Short-acting Beta-2 Agonists (SABAs) for Acute Asthma in Adults and Adolescents

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • Related Summaries

  • Overview

  • Classification of Severity of Asthma Exacerbations

  • KeyboardArrowRight

    Recommendations from Professional Organizations

    • Global Initiative for Asthma (GINA)

    • British Thoracic Society and Scottish Intercollegiate Guidelines Network (BTS/SIGN)

  • KeyboardArrowRight

    Dosing in Acute Asthma Exacerbation/Urgent Care Setting

    • Inhaled short-acting beta-2 agonists

    • Beta-2 agonists

    • Albuterol dose comparisons

    • Albuterol metered-dose inhaler frequency comparisons

    • Continuous vs. intermittent beta-agonist therapy

    • Dosing protocols

  • KeyboardArrowRight

    Delivery Methods

    • Comparisons of delivery via metered dose inhaler (MDI) vs. nebulizer

    • IV beta-2 agonists

  • KeyboardArrowRight

    Comparative Efficacy

    • Levalbuterol

    • Formoterol

    • Isoetharine

  • Adverse Events

  • KeyboardArrowRight

    Specific Patient Populations

    • Intubated patients

  • KeyboardArrowRight

    Guidelines and Resources

    • KeyboardArrowRight

      Guidelines

      • International guidelines

      • United States guidelines

      • United Kingdom guidelines

      • Australian and New Zealand guidelines

    • Review articles

  • Patient Information

  • KeyboardArrowRight

    ICD Codes

    • ICD-9 codes

    • ICD-10 codes

  • KeyboardArrowRight

    References

    • General references used

    • Recommendation grading systems used

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Deputy Editor
Terence K. Trow MD, FACP, FCCP
KeyboardArrowDown
Affiliations

Deputy Editor of Pulmonary, Critical Care, and Sleep Medicine; Connecticut, United States; Ex-Director of the Yale Pulmonary Vascular Disease Program, Associate Clinical Professor of Medicine, Yale University School of Medicine; Connecticut, United States

Conflicts of Interest

Dr. Trow declares no relevant financial conflicts of interest.

CheckCircle

top